A5034368675- Glaucoma and retinal disorders
- Retinal Diseases and Treatments
- Ocular Surface and Contact Lens
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Neurological Disorders and Treatments
- Ophthalmology and Eye Disorders
- COVID-19 Digital Contact Tracing
- Ophthalmology and Visual Impairment Studies
- Neurological and metabolic disorders
- Corneal surgery and disorders
- Human Mobility and Location-Based Analysis
- Clinical practice guidelines implementation
- Vasculitis and related conditions
- Tumors and Oncological Cases
- Cardiovascular Disease and Adiposity
- Genetic and rare skin diseases.
- Syphilis Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Hedgehog Signaling Pathway Studies
- Mobile Health and mHealth Applications
- Trauma and Emergency Care Studies
- Retinal and Macular Surgery
Complejo Hospitalario Universitario de Santiago
2012-2024
Universidad de las Américas Puebla
2021
Universidade de Santiago de Compostela
2007-2020
Abstract Background/Objectives To evaluate the efficacy and safety of preservative-free latanoprost eye drop emulsion in reducing intraocular pressure (IOP) versus preserved open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods A Phase III non-inferiority study randomised patients with OAG/OHT 1:1 to receive latanoprost. The primary endpoint was change from baseline peak (9:00 A.M. ± 1 h) trough (4:00 P.M. IOP at Week 12 (non-inferiority margin: 95% confidence interval for...
A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety a topical preservative-free tafluprost (0.0015%) timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) ocular hypertension (OHT) demonstrating insufficient response to beta-receptor blockers or prostaglandin analogue (PGA) monotherapy. Mean intraocular pressure (IOP) change from baseline was measured at study visits following...
Purpose: Data are presented from ophthalmology clinics in Spain participating the VISIONARY study, examining effectiveness, tolerability, and safety of preservative-free tafluprost (0.0015%) timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) treatment OAG OHT. Methods: An observational, multicenter prospective study examined outcomes following a switch to PF FC adult OAG/OHT patients demonstrating insufficient response beta-blocker or prostaglandin analog (PGA) monotherapy....
Purpose. To evaluate efficacy of intravitreal triamcinolone (IVT) and bevacizumab (IVB) as adjunctive treatments to panretinal photocoagulation (PRP) in proliferative diabetic retinopathy (PDR). Methods. In 60 eyes 45 patients with PDR, PRP (PRP group), IVT (IVT or IVB (IVB group) was performed. Regression new vessels (NV), changes best-corrected visual acuity (BCVA), central macular thickness (CMT), contrast sensitivity at 1,2, 6 months were evaluated. Results. Initial mean numbers active...
The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-optimally controlled topical prostaglandin analogue (PGA) beta-blocker monotherapy. Current subanalyses have examined these data according to baseline A European, prospective, observational included adults (aged...
Objective To characterize and describe clinical experience with childhood-onset non-infectious uveitis.
Purpose To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU).Methods An observational, retrospective, multicenter study was done. Changes best-corrected visual acuity (BCVA), inflammatory activity parameters, central retinal thickness (CRT), occurrence adverse events (AE) developed during follow-up were recorded.Results A total 82 eyes from 41 60 years age older treated included. significant improvement BCVA (71.5 to 75.4 letters, p = .001) CRT...
Analysis and comparison of country-level data from the VISIONARY study, examining treatment outcomes with topical fixed-dose combination preservative-free tafluprost (0.0015%) timolol (0.5%) (PF tafluprost/timolol FC) in adults open-angle glaucoma (OAG) ocular hypertension (OHT) who were insufficiently treated or unable to tolerate either beta-blocker prostaglandin analogue (PGA) monotherapy.A European, prospective, observational study was conducted 11 countries. Adults OAG/OHT switched PF...
Abstract Purpose The VISIONARY study assessed, in a real‐world clinical practice setting, the efficacy of preservative‐free tafluprost/timolol fixed‐dose combination (PF FC) adults with open‐angle glaucoma (OAG) or ocular hypertension (OHT) who did not achieve an adequate response to initial prostaglandin (PGA) beta‐blocker (BB) monotherapy. This analysis examined results reported by 7 countries (Italy, Hungary, Spain, Russia, UK, Latvia and Norway) enrolling >10 patients. Methods...
The pandemic from 2019 has led us to the implementation of different protocols reduce number infections per day and avoid overwhelming health centers. Until 2021, implemented methodologies stop continuous growth have greatly reduced infections, but they are not enough for society. Thus, we propose Risco, an application that will aid only in reduction via early detection contact with infected people by providing real time analytics tracing support improve awareness user location data.